29 June 2021 in British Journal of Cancer
Background: Clinically, metastatic rectal cancer has been considered a subset of left-sided colon cancer. However, heterogeneity has been proposed to exist between high and middle/low rectal cancers. We aimed to examine the efficacy of anti-epidermal growth factor receptor (EGFR) treatment for middle/low rectal and left-sided colon cancers. Methods: This study enrolled 609 patients with metastatic colorectal cancer who were treated with anti-EGFR therapy. They were divided into groups based on primary tumour locations: the right-sided colon, the left-sided colon or the middle/low rectum. The efficacy of first-line and non-first-line anti-EGFR treatment was analysed. Genomic differences in colorectal cancer data from The Cancer Genome Atlas (TCGA) were investigated and visualised with OncoPrint and a clustered heatmap. Results: On first-line anti-EGFR treatment, patients with middle/low rectal tumours had significantly lower progression-free survival, overall survival, and overall response rates (6.8 months, 27.8 months and 43%, respectively) than those with left-sided colon cancer (10.1 months, 38.3 months and 66%, respectively). Similar outcomes were also identified on non-first-line anti-EGFR treatment. In TCGA analysis, rectal tumours displayed genetic heterogeneity and shared features with both left- and right-sided colon cancer. Conclusions: Anti-EGFR treatment has lower efficacy in metastatic middle/low rectal cancer than in left-sided colon cancer.
5 December 2022 in Age and Ageing
An optimal antithrombotic strategy for patients aged 80 years or older with atrial fibrillation (AF) remains elusive. Using a systematic review with traditional and network meta-analysis, we investigated outcomes in AF patients ≥80 years treated with different antithrombotic strategies. We searched eligible randomised controlled trials (RCTs) and observational studies from MEDLINE, EMBASE, Cochrane Library and Web of Science databases from inception to 16 December 2021. Research comparing treatment outcomes of novel oral anticoagulants (NOACs), aspirin, vitamin K antagonists (VKAs) or no oral anticoagulant/placebo therapy in patients ≥80 years with AF were included. Outcomes were stroke or systemic embolism (SSE), major bleeding, all-cause mortality, intracranial bleeding (ICH) and gastrointestinal bleeding. Traditional and network meta-analyses were performed. Net clinical benefit integrating SSE and major bleeding was calculated. Fifty-three studies were identified for analysis. In the meta-analysis of RCTs, risk of SSE (risk ratio [RR]: 0.82; 95% confidence interval [CI]: 0.73–0.99) and ICH (RR: 0.38; 95% CI: 0.28–0.52) was significantly reduced when NOACs were compared with VKAs. Network meta-analysis of RCTs demonstrated that edoxaban (P-score: 0.8976) and apixaban (P-score: 0.8528) outperformed other antithrombotic therapies by showing a lower major bleeding risk and better net clinical benefit. Both traditional and network meta-analyses from RCTs combining with observational studies showed consistent results. In patients aged 80 years or older with AF, NOACs have better outcomes than VKAs regarding efficacy and safety profiles. Edoxaban and apixaban may be preferred treatment options since they are safer than other antithrombotic strategies.
30 June 2026 in Arthroscopy
14 December 2025 in Journal of Hand Surgery (European Volume)
Introduction: The aim of the study was to compare a radiocarpal approach with or without a midcarpal exploration to determine outcomes and incidence of recurrences following arthroscopic excision of dorsal wrist ganglions. Methods: This retrospective study included 39 patients who underwent arthroscopic excision of dorsal wrist ganglions with a radiocarpal approach alone and 32 patients who received radiocarpal excision with midcarpal exploration. Outcomes assessed at 1 year follow-up included Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) scores, pain relief, patient satisfaction, complications and recurrence. Pre- and postoperative MRI images were used to classify the ganglions into four types based on their origin and location. Postoperative MRI was performed in cases of suspected recurrence. Results: One year postoperatively, QuickDASH scores, pain relief and patient satisfaction were similar in both groups. Complications were minimal and comparable between groups. Recurrence occurred in seven patients in the radiocarpal excision group and in one patient who underwent radiocarpal excision with midcarpal exploration. Magnetic resonance imaging analysis of the eight recurrences revealed five type 2 lesions (midcarpal), one type 3 lesion (radiocarpal) and two type 4 lesions (combined radiocarpal and midcarpal), indicating that seven of eight recurrences involved the midcarpal joint. Conclusion: Routine midcarpal joint exploration during arthroscopic excision of dorsal wrist ganglions appeared to reduce recurrence at 1 year without negatively impacting patient outcomes. Level of Evidence: III
8 September 2026 in The Journal of Arthroplasty